Catalyst

Slingshot members are tracking this event:

Pacira (PCRX) Expects Exparel Phase 3 Topline Data by end of 2016 (Bracial Plexus Block in Total Shoulder Arthroplasty or Rotator Cuff Repair)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PCRX

100%

Additional Information

Additional Relevant Details "Pacira initiated two Phase 3 clinical trials that will serve as the basis of the supplemental New Drug Application (sNDA) to be filed for EXPAREL use in nerve block to provide postsurgical analgesia. One study will assess brachial plexus block with EXPAREL in patients undergoing total shoulder arthroplasty or rotator cuff repair. The second study will evaluate femoral nerve block with EXPAREL for patients undergoing total knee arthroplasty."
https://globenewswir...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Exparel, Phase 3 Topline Data, Q4 2016